In the first half of 2026, the overall profitability of A-share biomedical companies improved markedly, handed over outstanding report cards in resilient development, and innovation-driven and domestic and foreign market expansion became the core driving force for performance growth. As of August 3, 104 A-share biomedical companies have disclosed their results for the first half of the year. Judging from the lower limit of the forecast net profit increase, 67 companies expect net profit growth. In addition, 10 companies, including Yao Ming Kangde, Wohua Pharmaceutical, and Zejing Pharmaceutical, disclosed semi-annual reports, and 7 of them achieved year-on-year increases in net profit or reversed losses.

In the first half of 2026, the overall profitability of A-share biomedical companies improved markedly, handed over outstanding report cards in resilient development, and innovation-driven and domestic and foreign market expansion became the core driving force for performance growth. As of August 3, 104 A-share biomedical companies have disclosed their results for the first half of the year. Judging from the lower limit of the forecast net profit increase, 67 companies expect net profit growth. In addition, 10 companies, including Yao Ming Kangde, Wohua Pharmaceutical, and Zejing Pharmaceutical, disclosed semi-annual reports, and 7 of them achieved year-on-year increases in net profit or reversed losses.